Quchang Ouyang

2.5k total citations
80 papers, 1.0k citations indexed

About

Quchang Ouyang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Quchang Ouyang has authored 80 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 26 papers in Cancer Research. Recurrent topics in Quchang Ouyang's work include Advanced Breast Cancer Therapies (38 papers), HER2/EGFR in Cancer Research (30 papers) and Cancer Treatment and Pharmacology (22 papers). Quchang Ouyang is often cited by papers focused on Advanced Breast Cancer Therapies (38 papers), HER2/EGFR in Cancer Research (30 papers) and Cancer Treatment and Pharmacology (22 papers). Quchang Ouyang collaborates with scholars based in China, United States and Japan. Quchang Ouyang's co-authors include Binghe Xu, Zhongsheng Tong, Zefei Jiang, Fei Ma, Jianjun Zou, Xiaoyu Zhu, Shusen Wang, Wěi Li, Huiping Li and Xichun Hu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Quchang Ouyang

76 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Quchang Ouyang China	15	718	476	250	181	178	80	1.0k
Ruigang Cai China	17	807 1.1×	391 0.8×	452 1.8×	210 1.2×	204 1.1×	67	1.1k
Armando Orlandi Italy	17	519 0.7×	248 0.5×	248 1.0×	100 0.6×	192 1.1×	90	879
Ashok K. Vaid India	15	781 1.1×	455 1.0×	259 1.0×	193 1.1×	188 1.1×	54	1.1k
Yuka Asano Japan	23	1.0k 1.4×	289 0.6×	470 1.9×	91 0.5×	278 1.6×	111	1.6k
Shikai Wu China	18	461 0.6×	284 0.6×	186 0.7×	85 0.5×	159 0.9×	73	796
Cory Batenchuk United States	10	660 0.9×	356 0.7×	183 0.7×	85 0.5×	135 0.8×	16	881
Yanxia Shi China	18	571 0.8×	256 0.5×	213 0.9×	141 0.8×	311 1.7×	76	982
Shinobu Masuda Japan	16	496 0.7×	242 0.5×	412 1.6×	146 0.8×	220 1.2×	88	933
Carlos A. Castañeda Peru	15	461 0.6×	167 0.4×	250 1.0×	55 0.3×	286 1.6×	66	893
Guochun Zhang China	19	572 0.8×	478 1.0×	525 2.1×	92 0.5×	456 2.6×	62	1.1k

Countries citing papers authored by Quchang Ouyang

Since Specialization

Citations

This map shows the geographic impact of Quchang Ouyang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Quchang Ouyang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Quchang Ouyang more than expected).

Fields of papers citing papers by Quchang Ouyang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Quchang Ouyang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Quchang Ouyang. The network helps show where Quchang Ouyang may publish in the future.

Co-authorship network of co-authors of Quchang Ouyang

This figure shows the co-authorship network connecting the top 25 collaborators of Quchang Ouyang. A scholar is included among the top collaborators of Quchang Ouyang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Quchang Ouyang. Quchang Ouyang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Fan, Hong Wang, Shan Wang, et al.. (2025). LBA23 Sacituzumab tirumotecan (sac-TMT) vs investigator's choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Results from the randomized, multi-center phase III OptiTROP-Breast02 study. Annals of Oncology. 36. S1568–S1569.

Song, Erqun, Herui Yao, Yuzhen Yin, et al.. (2025). LBA19 SHR-A1811 versus pyrotinib plus capecitabine in human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (BC): A multicenter, open-label, randomized, phase III study (HORIZON-Breast01). Annals of Oncology. 36. S1564–S1565. 2 indexed citations

Li, Xiao, Quchang Ouyang, Xiaoqing Liu, et al.. (2025). π‐PhenoDrug: A Comprehensive Deep Learning‐Based Pipeline for Phenotypic Drug Screening in High‐Content Analysis. Advanced Intelligent Systems. 7(6).

Hu, Xichun, Leiping Wang, Jian Zhang, et al.. (2024). ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).. Journal of Clinical Oncology. 42(16_suppl). 1020–1020. 7 indexed citations

Wu, Jiong, Jian Zhang, Man Li, et al.. (2024). A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1047–1047. 1 indexed citations

Shao, Xiying, Zhanhong Chen, Xinshuai Wang, et al.. (2024). Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial. Journal of Translational Internal Medicine. 12(5). 466–477. 5 indexed citations

Hu, Zhe-Yu, Min Yan, Huihua Xiong, et al.. (2023). Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial. BMC Medicine. 21(1). 226–226. 7 indexed citations

Zhang, Qingyuan, Wei Li, Xichun Hu, et al.. (2023). Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial. PubMed. 4. 18–18. 4 indexed citations

Liu, Binliang, Ning Xie, Zhe-Yu Hu, et al.. (2023). Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody. The Breast. 72. 103597–103597. 6 indexed citations

10.

Xie, Ning, Xiaobo Hu, Yu Tang, et al.. (2022). Impact of surgical management of primary tumors in stage IV breast cancer patients: a retrospective observational study based on SEER database. BMJ Open. 12(2). e054135–e054135. 2 indexed citations

11.

Fan, Ying, Tao Sun, Zhimin Shao, et al.. (2021). Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators. JAMA Oncology. 7(10). e213428–e213428. 27 indexed citations

12.

Chen, Shanshan, Yiqun Han, Quchang Ouyang, et al.. (2021). Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy. BMC Cancer. 21(1). 341–341. 4 indexed citations

13.

Liu, Jingyu, Jing Li, Hui Wang, et al.. (2019). Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients. Journal of Translational Medicine. 17(1). 27–27. 18 indexed citations

14.

Ma, Fei, Quchang Ouyang, Wěi Li, et al.. (2019). Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. Journal of Clinical Oncology. 37(29). 2610–2619. 247 indexed citations

15.

Yuan, Peng, Xichun Hu, Tao Sun, et al.. (2019). Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. European Journal of Cancer. 112. 57–65. 68 indexed citations

16.

Hu, Zhe-Yu, et al.. (2018). Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor. Clinical Breast Cancer. 18(5). e1149–e1163. 11 indexed citations

17.

Li, Junjie, Zhimin Shao, Binghe Xu, et al.. (2018). Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China. Medicine. 97(21). e10350–e10350. 13 indexed citations

18.

Jiang, Zefei, W. Li, Xin Hu, et al.. (2018). Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer. Annals of Oncology. 29. viii709–viii709. 4 indexed citations

19.

Li, Jianbin, Shusen Wang, Yongsheng Wang, et al.. (2017). Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China. The Oncologist. 22(11). 1333–1338. 35 indexed citations

20.

Yan, Mingfei, et al.. (2017). [Circulating tumor cells in patients with breast tumors were detected by a novel device: a multicenter, clinical trial in China].. PubMed. 97(24). 1857–1861. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact